FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL
--------------

hours per response:

OMB Number: 3235-0287 Estimated average burden

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	<u> </u>	·	erivative Securities Acquired, Disposed of, or Be		<u> </u>	
(City)	(State)	(Zip)				
PLAINFIELD					Form filed by More the Person	an One Reporting
(Street)	NJ	07080	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual Line)	dual or Joint/Group Fili	
100 CORPORAT	TE COURT					
C/O PTC THER	APEUTICS,	INC.	06/28/2019		SVP, Finance	& CAU
(Last)	(First)	(Middle)	Date of Earliest Transaction (Month/Day/Year)	X	Officer (give title below)	Other (specify below)
1. Name and Addres <u>Utter Christin</u>		Person*	2. Issuer Name and Ticker or Trading Symbol PTC THERAPEUTICS, INC. [ PTCT ]		onship of Reporting Pe all applicable) Director	10% Owner

Table 1 - Non-Delivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(111511.4)		
Common Stock	06/28/2019		<b>M</b> <sup>(1)</sup>		236	A	\$27.05	5,173	D			
Common Stock	06/28/2019		S <sup>(1)</sup>		236	D	\$45	4,937	D			
Common Stock	06/28/2019		M <sup>(1)</sup>		49	A	\$30.86	4,986	D			
Common Stock	06/28/2019		S <sup>(1)</sup>		49	D	\$45	4,937	D			
Common Stock	06/28/2019		M <sup>(1)</sup>		703	A	\$18.01	5,640	D			
Common Stock	06/28/2019		S <sup>(1)</sup>		703	D	\$45	4,937	D			
Common Stock	07/01/2019		M <sup>(1)</sup>		3,133	A	\$27.05	8,070	D			
Common Stock	07/01/2019		S <sup>(1)</sup>		3,133	D	\$45.149(2)	4,937	D			
Common Stock	07/01/2019		M <sup>(1)</sup>		641	A	\$30.86	5,578	D			
Common Stock	07/01/2019		S <sup>(1)</sup>		641	D	\$45.149(2)	4,937	D			
Common Stock	07/01/2019		M <sup>(1)</sup>		9,297	A	\$18.01	14,234	D			
Common Stock	07/01/2019		S <sup>(1)</sup>		9,297	D	\$45.149(2)	4,937	D			

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deri Sec Acq (A) ( Disp of (I	osed 0) tr. 3, 4	6. Date Exerc Expiration Da (Month/Day/\)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right To Buy)	\$27.05	06/28/2019		M <sup>(1)</sup>			236	(3)	01/28/2024	Common Stock	236	\$27.05	3,133	D	
Stock Option (Right To Buy)	\$30.86	06/28/2019		M <sup>(1)</sup>			49	(4)	01/03/2026	Common Stock	49	\$30.86	10,951	D	
Stock Option (Right To Buy)	\$18.01	06/28/2019		M <sup>(1)</sup>			703	(5)	01/02/2028	Common Stock	703	\$18.01	39,297	D	
Stock Option (Right To Buy)	\$27.05	07/01/2019		M <sup>(1)</sup>			3,133	(3)	01/28/2024	Common Stock	3,133	\$0	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
	Conversion or Exercise Price of Derivative	e (Month/Day/Year)	Date	Date	Date	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)	action (Instr.	of Deri Sec Acq (A) ( Disp of (I	oosed D) tr. 3, 4	6. Date Exerc Expiration Da (Month/Day/\)	ate	7. Title an of Securit Underlyin Derivative (Instr. 3 an	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							
Stock Option (Right To Buy)	\$30.86	07/01/2019		M <sup>(1)</sup>			641	(4)	01/03/2026	Common Stock	641	\$30.86	10,310	D				
Stock Option (Right To Buy)	\$18.01	07/01/2019		M <sup>(1)</sup>			9,297	(5)	01/02/2028	Common Stock	9,297	\$18.01	30,000	D				
Stock Option (Right To Buy)	\$490.8							(3)	04/27/2021	Common Stock	74		74	D				
Stock Option (Right To Buy)	\$218.4							(3)	01/10/2022	Common Stock	21		21	D				
Stock Option (Right To Buy)	\$40.45							(3)	09/23/2024	Common Stock	4,688		4,688	D				
Stock Option (Right To Buy)	\$51							(3)	01/02/2025	Common Stock	17,800		17,800	D				
Stock Option (Right To Buy)	\$11.23							(6)	01/02/2027	Common Stock	6,300		6,300	D				
Stock Option (Right To Buy)	\$13.1							(7)	06/02/2027	Common Stock	6,250		6,250	D				
Stock Option (Right To Buy)	\$33.02							(8)	01/21/2029	Common Stock	42,500		42,500	D				
Stock Option (Right To	\$33.02							(9)	01/21/2029	Common Stock	10,100		10,100	D				

# Explanation of Responses:

- 1. The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 9, 2018.
- 2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$45.00 to \$45.15 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 3. Currently exercisable.

Buy)

- 4. This option was granted on January 4, 2016 and vests over four years, with 25% of the shares underlying the option vested on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
- 5. This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
- 6. This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
- 7. This option was granted on June 2, 2017, and vests over two years, with 50% of the shares underlying the option vesting on June 2, 2018, and an additional 12.5% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on September 2, 2018.
- 8. This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
- 9. This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.

## Remarks:

/s/ Avraham S. Adler, attorneyin-fact
\*\* Signature of Reporting Person

07/02/2019

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.